Gene therapies were supposed to be competition-proof. They are scientifically complex, require bespoke manufacturing, often go after small patient populations and can cost millions per dose.
But that assumption is being tested by a wave …
Basecamp Research’s Trillion Gene Atlas will bring together genomic data from millions of species to guide AI-powered design of new medicines.
Plus, news about Eledon, Sobi, Ovid and CytomX: 🗓️ Ionis updates prion disease study timelines: The California oligonucleotide powerhouse has pushed back the primary completion
Johnson & Johnson secured an FDA approval on Wednesday for a psoriasis pill it expects to become a megablockbuster. Regulators gave the green light to
Johnson & Johnson’s much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.
Always be in the clinic — those are the “ABCs” of biotech, drug development veteran Briggs Morrison tells Endpoints News. And that’s precisely where Morrison’s
Gene therapies were supposed to be competition-proof. They are scientifically complex, require bespoke manufacturing, often go after small patient populations and can cost millions per dose.
But that assumption is being tested by a wave …